HC Wainwright Has Positive Outlook for ELTX FY2026 Earnings

Elicio Therapeutics, Inc. (NASDAQ:ELTX) – HC Wainwright boosted their FY2026 EPS estimates for shares of Elicio Therapeutics in a report issued on Tuesday, November 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($1.60) for the year, up from their previous forecast of ($1.83). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Elicio Therapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Elicio Therapeutics’ Q4 2026 earnings at ($0.31) EPS, Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.27) EPS and FY2027 earnings at ($1.12) EPS.

ELTX has been the topic of a number of other research reports. B. Riley Financial decreased their target price on shares of Elicio Therapeutics to $8.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. Weiss Ratings upgraded Elicio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Finally, Wall Street Zen raised Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Elicio Therapeutics Stock Performance

Shares of ELTX opened at $1.63 on Thursday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.43 and a current ratio of 3.43. The company has a market capitalization of $46.14 million, a price-to-earnings ratio of -0.87 and a beta of 1.64. The company’s 50 day simple moving average is $1.85 and its 200 day simple moving average is $6.49. Elicio Therapeutics has a 1 year low of $1.25 and a 1 year high of $16.00.

Elicio Therapeutics (NASDAQ:ELTX) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.14.

Institutional Trading of Elicio Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELTX. HB Wealth Management LLC acquired a new position in shares of Elicio Therapeutics during the 1st quarter valued at about $112,000. Deutsche Bank AG purchased a new position in shares of Elicio Therapeutics during the 2nd quarter worth about $49,000. Bank of America Corp DE lifted its holdings in shares of Elicio Therapeutics by 1,225.2% during the 1st quarter. Bank of America Corp DE now owns 15,333 shares of the company’s stock worth $164,000 after acquiring an additional 14,176 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Elicio Therapeutics in the second quarter worth approximately $62,000. Finally, Ieq Capital LLC acquired a new stake in shares of Elicio Therapeutics in the third quarter worth approximately $47,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated. Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.